Proteins and Peptides
8 January 2016
Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity8 January 2016
Molecular Partners to Conduct Phase II Trial of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Multiple Myeloma8 January 2016
Novo Nordisk files for regulatory approval of long-acting factor IX in the EU for the treatment of haemophilia B6 January 2016
Glide Technologies Announces Successful Proof-of-Concept With Novel Exenatide Solid Dose Formulation5 January 2016
Immune Pharmaceuticals Announces New Data with Topical Cyclosporine Nano-Capsules in Dermatology24 December 2015
Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis24 December 2015
Merz North America Announces FDA Approval Of XEOMIN® (incobotulinumtoxinA) For Treatment of Adult Upper Limb Spasticity23 December 2015
Sanofi Submits New Drug Application for the Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide22 December 2015
Amicus Therapeutics Commences Phase 1/2 Study of Novel ERT for Treatment of Pompe Disease22 December 2015
CSL Behring Submits Marketing Authorization Application to the European Medicines Agency for rVIII-SingleChain for Patients with Hemophilia A22 December 2015
Flamel Technologies Announces Positive Interim Results of a First-in-Man Clinical Trial With Medusa(TM) Exenatide21 December 2015
Baxalta’s ADYNOVATE Meets Endpoints in Phase 3 Study of Hemophilia A Patients Under 12 Years of Age19 December 2015
Bayer Receives Positive CHMP Opinion for BAY 81-8973 for the Treatment of Hemophilia A in Patients in EU18 December 2015
Novo Nordisk successfully completes fourth phase 3a trial with semaglutide in people with type 2 diabetes17 December 2015
FDA Approves Basaglar® (insulin glargine injection), a Long-Acting Insulin Treatment15 December 2015
EMA started the evaluation of Richter’s marketing authorisation application for biosimilar pegfilgrastim11 December 2015
Medtronic Announces FDA Approval of Infuse® Bone Graft for Three New Spine Surgery Indications9 December 2015
Coherus BioSciences Reports Update to CHS-1701 Program9 December 2015
Therabron Therapeutics Announces Favorable Infant Outcomes with Six-Month Follow-Up of a Phase 1b Recombinant Human CC10 Clinical Trial9 December 2015
Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the US for the treatment of type 1 and 2 diabetes9 December 2015
FDA Approves Kanuma(TM) (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D)9 December 2015
Baxalta Receives FDA Approval for VONVENDI, the First and Only Recombinant Treatment for Adults Affected by Von Willebrand DiseaseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports